Pacira BioSciences Reports First Quarter 2020 Financial Results and Business Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/9/2026
- After-Hours Movers: COO, AEO, NAVN, AVAV, TORO
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
Pacira Pharma (PCRX) Tops Q1 EPS by 22c, Revenues Beat
May 7, 2020 8:09 AM EDTPacira Pharma (NASDAQ: PCRX) reported Q1 EPS of $0.53, $0.22 better than the analyst estimate of $0.31. Revenue for the quarter came in at $105.7 million versus the consensus estimate of $102.82 million.
First Quarter 2020 Financial Results
Total revenues were $105.7 million in the first quarter of 2020, a 16% increase over the $91.3 million reported for the first quarter of 2019.EXPAREL net product sales were $101.3 million in the first quarter of 2020, a 12% increase over the $90.6 million reported for the first quarter of 2019.First quarter iovera° net product sales were $2.3 million. Pacira began recognizing sales of iovera° in April 2019... More